Skip to content

ENANTA PHARMACEUTICALS INC

ENTA

CIK 0001177648 · Pharmaceutical Preparations · Nasdaq

← back to feed
Revenue (TTM)
$69.01M
−3.4% YoY Q2 May 2026
Net Income (TTM)
−$65.93M
+29.4% YoY Q2 May 2026
EPS Diluted (TTM)
−$2.78
+29.9% YoY Q2 May 2026
Gross Margin
—
Q2 May 2026
Operating Margin
-96.4%
Q2 May 2026
Net Margin
-95.5%
Q2 May 2026
Free Cash Flow (TTM)
−$101.96M
Q2 May 2026
Cash
$34.93M
Q2 May 2026
Total Debt
—
Q2 May 2026
Shares Outstanding
29.08M sh
Q2 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings